Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Domainex and Ark Therapeutics Extend Drug Discovery Agreement
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Domainex Ltd has announced an extension of its research agreement with Ark Therapeutics Group Ltd (Ark). Under the terms of the agreement Domainex will continue to provide Ark with hit-finding and lead optimization services for drug discovery against novel and exciting therapeutic targets nominated by the company.
Domainex and Ark have been working closely together for several years, successfully combining Domainex’s capabilities in drug design and lead optimization with Ark’s disease and molecular biology expertise.
Domainex’s experienced research team specialize in the provision of medicinal chemistry, computer-aided drug design, biochemistry, and molecular biology services which are tailored to the specific needs of biotechnology companies and academic research groups. The company is also developing its own pipeline of pre-clinical drugs and targets.
Dr Trevor Perrior, Research Director of Domainex, commented: “Domainex is delighted that Ark has decided to extend our productive relationship. The synergy and teamwork between our respective scientists have been outstanding, and this collaboration has already resulted in the achievement of key breakthroughs against very challenging scientific goals.”
Dr. Perrior continued, “We look forward to taking these programmes to the next stage of their development, with the aim of delivering important new treatments for major life-threatening diseases. The renewal of this contract is a further illustration of the value that clients such as Ark place on the contribution that Domainex is able to bring to their drug research programmes.”
Domainex and Ark have been working closely together for several years, successfully combining Domainex’s capabilities in drug design and lead optimization with Ark’s disease and molecular biology expertise.
Domainex’s experienced research team specialize in the provision of medicinal chemistry, computer-aided drug design, biochemistry, and molecular biology services which are tailored to the specific needs of biotechnology companies and academic research groups. The company is also developing its own pipeline of pre-clinical drugs and targets.
Dr Trevor Perrior, Research Director of Domainex, commented: “Domainex is delighted that Ark has decided to extend our productive relationship. The synergy and teamwork between our respective scientists have been outstanding, and this collaboration has already resulted in the achievement of key breakthroughs against very challenging scientific goals.”
Dr. Perrior continued, “We look forward to taking these programmes to the next stage of their development, with the aim of delivering important new treatments for major life-threatening diseases. The renewal of this contract is a further illustration of the value that clients such as Ark place on the contribution that Domainex is able to bring to their drug research programmes.”
